Ablynx Regains Rights on Drugs Licensed to Pfizer, Sets Terms
Stock Chart for Pfizer Inc (PFE)
Ablynx NV (ABLX) said it regained the rights on its experimental TNF-alpha blocking medicines that were licensed to Pfizer Inc. (PFE) and agreed to pay Pfizer milestones of as much as $50 million following an eventual third-party alliance for the drugs as well as royalties on sales.
To contact the editor responsible for this story: John Martens at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.